NEW YORK – Investment bank BTIG has initiated coverage of Fulgent Genetics with a Buy rating and a $20 price target.
In a research note on Thursday, BTIG analyst Sung Ji Nam wrote that Fulgent has shown growth over the past several years.
NEW YORK – Investment bank BTIG has initiated coverage of Fulgent Genetics with a Buy rating and a $20 price target.
In a research note on Thursday, BTIG analyst Sung Ji Nam wrote that Fulgent has shown growth over the past several years.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.
Privacy Policy. Terms & Conditions. . Copyright © 2021 GenomeWeb, a business unit of Crain Communications. All Rights Reserved.